Memantine as an Additive Therapy in Patients With Traumatic Brain Injury
Status:
NOT_YET_RECRUITING
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
Memantine has shown promise in mitigating secondary brain injury in previous studies. One study demonstrated that early memantine administration in moderate TBI patients resulted in lower serum neuron-specific enolase levels and improved Glasgow Coma Scale scores. However, other trials investigating memantine's impact on long-term cognitive function in TBI patients have yielded mixed results. There is a need for well-controlled studies to determine the efficacy of memantine in improving neurological and cognitive outcomes in patients with TBI.